Aptose Biosciences (NASDAQ:APTO) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

APTO has been the subject of several other reports. Canaccord Genuity Group lowered their target price on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research note on Thursday, May 16th. HC Wainwright reaffirmed a buy rating and issued a $7.00 target price on shares of Aptose Biosciences in a research note on Friday, June 14th. Finally, Piper Sandler reaffirmed an overweight rating and issued a $5.00 target price on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $14.83.

Aptose Biosciences Price Performance

Shares of APTO opened at $0.76 on Friday. The firm has a 50 day simple moving average of $1.02 and a 200-day simple moving average of $1.57. Aptose Biosciences has a 1-year low of $0.71 and a 1-year high of $5.10. The stock has a market cap of $13.76 million, a price-to-earnings ratio of -0.12 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09. On average, equities analysts expect that Aptose Biosciences will post -2.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC lifted its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 40.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,666 shares of the biotechnology company’s stock after acquiring an additional 21,334 shares during the quarter. Annandale Capital LLC owned about 0.99% of Aptose Biosciences worth $209,000 as of its most recent filing with the Securities and Exchange Commission. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.